Omega-3 Fatty Acids Reduce Hyperlipidaemia Hyperinsulinaemia and Hypertension in Cardiovascular Patients

Yam D, Bott-Kanner G, Friedman J, Genin I, Klainman E, Shinitzky M

Homepage:
www.kup.at/jcbc

Online Data Base Search for Authors and Keywords
**Omega-3 Fatty Acids Reduce Hyperlipidaemia, Hyperinsulinaemia and Hypertension in Cardiovascular Patients**

D. Yam, J. Friedman, G. Bott-Kanner, I. Genin, M. Shinitzky, E. Klainman

Cardiovascular disease (CVD) is associated with hyperlipidaemia, hypertension and frequently with insulin resistance, which in general are not alleviated by antilipidaemic drugs. Our objective was to examine whether a supplemented diet containing eicosapentaenoic (EPA) and docosahexaenoic (DHA) omega-3 fatty acids (n-3 FAs), in addition to lecithin, extracts of rosemary and curcumin (n-3 FAs + supplements), can reduce the levels of serum lipids, insulin and hypertension in documented CVD patients (pts) treated by statins and/or bezafibrates.

In a double-blind placebo-controlled trial of parallel design, 78 pts, age 69.7 ± 4.1 years treated by antilipidaemic drugs, were randomly assigned to receive daily 7 g of the n-3 FAs + supplements in a form of a bread spread (Yamega Ltd, Israel) or analogous spread made of olive oil as placebo. The participants were recommended to reduce the consumption of omega-6 fatty acids for 12 weeks. The average values ± SD before and after dietary supplementation were compared.

62 pts (34 in the n-3 FAs + supplements group and 28 in the control group) completed the study. In the n-3 FAs + supplements group we observed a significant decrease (p < 0.05) of total serum cholesterol (17.2 %), LDL-cholesterol (16.2 %), triglycerides (39.6 %), and insulin (35.2 %) in the hyperinsulinaemic subjects (> 20 microunits/ml). Hypertension (> 140/90 mmHg) was positively correlated to hyperinsulinaemia, decreased significantly especially in the systolic blood pressure. No significant changes in HDL-cholesterol and glucose were observed. In the placebo group we observed a significant decrease (p < 0.05) in the LDL-cholesterol values of 10.6 % but no significant changes in the other parameters. No side effects were reported during the study in any of the participants. Our findings demonstrate that the incorporation of the dietary supplement containing EPA and DHA omega-3 FAs supplemented with lecithin, rosemary and curcumin can reduce significantly the risk factors for CVD. *J Clin Basic Cardiol* 2002; 5: 229–31.

**Key words:** hypertension, hyperlipidaemia, hyperinsulinaemia, cardiovascular disease, omega-3 fatty acids

---

The human race evolved consuming a diet that contained about equal amounts of n-3 and n-6 essential fatty acids. Over the past century there has been an enormous increase in the consumption of n-6 fatty acids due to the increased intake of vegetable oils in particular from corn, sunflower, safflower, cottonseed and soybeans. Today, the ratio of n-6 to n-3 fatty acids in the Western diet, including ranges from approximately 10:1 to 20:1 in comparison to the traditional range of 1–2:1 [1, 2]. The high intake of n-6 fatty acids affects a variety of pathophysiological processes, ranging from immune-inflammatory reactions to atherogenesis and tumorigenesis [3], increased susceptibility of LDL to oxidation [4, 5], enhanced prothrombotic and proaggregatory processes which lead to high blood viscosity, vasospasm, vasoconstriction and decreased bleeding time [6], reduced level of HDL-cholesterol [7, 8] which together lead to an increased risk for coronary thrombosis, coronary heart disease, acute myocardial infarction and mortality [7].

Furthermore, a high intake of linoleic n-6 FA increases the secretion of insulin, and/or reduces insulin catalobism [9, 10], causing impaired insulin actions [11, 12], and leading to insulin resistance syndromes [13, 14], termed syndrome X [13]. On the other hand, epidemiological, clinical and experimental studies have shown an inverse correlation between consumption of fish or other sources of dietary n-3 fatty acids and cardiovascular impairments [15], risk of ischaemic heart disease [16] and incidence of sudden cardiac death [17, 18]. In addition, a series of studies attributed to n-3 FA attenmation in the development of atherosclerosis or restenosis [19], stabilization of arrhythmia [17, 18], changes in the LDL-cholesterol composition with less atherogenic LDL particles and reduction of apolipoprotein B [20, 21], lipoprotein (a) [22], fasting and postprandial plasma triacylglycerol [20, 23] and hypertension [24, 25]. No less important is that n-3 FAs were found to reduce hyperinsulinaemia [26] and insulin resistance [10]. Numerous reports attributed to extracts of curcumin and rosemary therapeutic antioxidant activities, prevention of spasmodic disorders, inflammatory diseases, atherosclerosis and ischaemic heart diseases [27–30]. In the present study it was demonstrated that a diet containing n-3 fatty acids supplemented with lecithin, curcumin and rosemary extracts, improves dyslipidaemia, hypertension and hyperinsulinaemia in CVD pts and may therefore be used as an effective adjuvant to antilipidaemic drugs.

**Materials and Methods**

**Patients and Randomization**

In a double-blind placebo-controlled trial of parallel design, 78 documented CVD pts (by coronary angiogram or at least by 201-Thallium heart scan), age 69.7 ± 4.1 y, were enrolled. The clinical characteristics of the pts were as follows: 4 pts with post myocardial infarction (MI) with stable anginal syndrome (AP), 11 pts with post MI and no AP, 25 pts with stable AP, 38 pts without symptoms, 7 of them were post percutaneous transluminal coronary angioplasty and 5 pts were post coronary artery bypass grafting, and 4 pts with congestive heart failure. None of the pts were obese or alcohol abusers. They were followed by the Mishmar Hayarden Cardiac and Rehabilitation Institute-Givataym, and randomly assigned to...
receive 7 g/d of a dietary concentrated supplement (n-3 FAs+supplements group; composition given below) or placebo, and recommended to reduce the consumption of omega-6 fatty acids for 12 weeks. The eligibility criteria were existence of CVD and dyslipidaemia treated by statins and/or bezafibrates for at least 3 months before entering the study without satisfactory results, so that an increase of medication doses had been considered. The antilipidemic drug treatment was continued during the study.

**Results**

62 pts, 34 in the omega-3 FAs + supplements group and 28 in the placebo group, completed the study. Table 1 summarizes the blood test results before and at the end of the study in both groups. The results in the omega-3 FAs + supplements group indicated a significant decrease (p < 0.05) of total cholesterol (17.2 %), LDL-cholesterol (16.2 %), triglycerides (39.6 %) and insulin (35.2 %) in the hyperinsulinaemic pts, (18 out of 34), and no significant changes in the HDL-cholesterol and glucose values. 9 out of the 18 hyperinsulinaemic pts showed high values of systolic blood pressure (175 ± 12 mmHg) which decreased at the end of the study to 130.8 ± 3 mmHg while diastolic values decreased from 95 ± 3 to 82.5 ± 3 mmHg.

In the placebo group a significant decrease in the LDL-cholesterol of 10.6 % was observed with no changes in the other parameters. No side effects were reported in any of the participants of both groups.

**Discussion**

Lipid lowering drugs like the statins lower LDL-cholesterol levels, increase HDL-cholesterol, and reduce triglycerides [31]. However, the CVD pts in our study, despite being treated by these antilipidaemic drugs, presented before the study high blood cholesterol, LDL-cholesterol and very high values of triglycerides (see Tab. 1). In addition, 34 out of 62 pts, presented also high insulin levels (> 20 mU/ml) and 16 of them were under hypertension.

The best evidence for the influences of dietary fats on human health is provided by the Japanese people. During the past 40 years, the average intake of total fats in Japan has increased to approx. 60 g/day, still considerably below the levels in Western countries.

The average intake of n-6 and n-3 FA in Japan has also increased from 4 g/d and 2g/d to 12g/d and 3g/d respectively, so that the ratio between n-6 and n-3 FA increased from 2 to 4 while in the Western countries the ratio is 10–20 [1]. According to Okuyama et al. [32] this increase in n-6 FA and relative n-3 deficiency are major risk factors for cancers, cardiovascular and cerebrovascular diseases and also for allergic hyperreactivity.

Hypertriglyceridaemia and hypertension are the most common abnormalities associated with hyperinsulinaemia and insulin resistance [13, 14] and strong predictors of risk for coronary heart disease (CHD) and myocardial infarction. Elevated plasma triacylglycerol concentrations are associated with other CHD risk factors, namely reduced HDL-cholesterol and a preponderance of highly atherogenic, LDL-cholesterol. Other pathological responses, such as impaired coagulation and pancreatitis, have also been attributed to hypertriglyceridaemia [33].

Several factors may lead to hyperinsulinaemia and insulin resistance, among them high consumption of linoleic n-6 FA. On the
other hand, n-3 FA prevent hyperinsulinemia [26] and insulin resistance [10]. In addition, recent studies attributed to curcumin and rosemary extracts antioxidant activities in addition to prevention of spasmotic disorders, inflammatory diseases, atherosclerosis, and ischemic heart diseases [27–30].

In line with this evidence we may attribute the beneficial changes observed in the blood profile (Tab. 1) of the n-3 FAs + suppl pts group, to n-3 FA and the other active ingredients in the dietary spread. The results of this study reinforce many other studies showing that n-3 FA, especially when combined with curcumin and rosemary extracts, may alleviate and/or prevent CHD and other related diseases [16–23]. In addition, the results of this study indicate that the combination of simvastatin and fish oil has better therapeutic effects than simvastatin alone [31], which deserve further investigation.

Another aspect to be considered is the statins’ pharmacological and clinical effects. In general, the safety and tolerability profiles for all statins currently in use is of less than 2% incidence of undesirable effects. The most common adverse effects of simvastatin are gastrointestinal disturbance, myositis and myopathy. However, rhabdomyolysis leading to renal failure [34] and thyroid follicular adenoma [35] were also reported. Intake of n-3 fatty acid may therefore permit the reduction statins doses, and thus alleviate the adverse effects.

Conclusion

Many studies have shown that diets may interfere with a series of risk factors of CVD not modulated by antilipemic drugs. Our study confirms and reinforces studies showing that n-3 FAs combined with lecithin, curcumin and rosemary extracts have an important beneficial influence on dyslipidaemia, hypertension and hyperinsulinemia.

References

Mitteilungen aus der Redaktion

Besuchen Sie unsere
zeitschriftenübergreifende Datenbank

☐ Bilddatenbank  ☑ Artikelldatenbank  ☑ Fallberichte

e-Journal-Abo
Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.
Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.
Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

☑ Bestellung e-Journal-Abo

Haftungsausschluss

Bitte beachten Sie auch diese Seiten:
Impressum  Disclaimers & Copyright  Datenschutzerklärung